My watch list  


Systematic (IUPAC) name
sodium 2-sulfanylethanesulfonate
CAS number 19767-45-4
ATC code R05CB05 V03AF01
PubChem 29769
Chemical data
Formula C2H5NaO3S2 
Mol. mass 164.181 g/mol
Pharmacokinetic data
Bioavailability 45–79% (Oral)
Metabolism Oxidised in circulation
Half life 0.36–8.3 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

B1 (Au), B (U.S.)

Legal status

S4 (Au), POM (UK), ℞-only (U.S.)

Routes Oral, intravenous

Mesna (INN) (pronounced /ˈmɛznə/) is an adjuvant used in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is currently marketed by Baxter as Uromitexan® and Mesnex®.

Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites such as acrolein. Mesna assists to neutralise these metabolites by binding through its sulfhydryl-moieties, and also increases urinary excretion of cysteine.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mesna". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE